HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roberto Ciccocioppo Selected Research

Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)

10/2017Hypothalamic CRF1 receptor mechanisms are not sufficient to account for binge-like palatable food consumption in female rats.
8/2014Role of bed nucleus of the stria terminalis corticotrophin-releasing factor receptors in frustration stress-induced binge-like palatable food consumption in female rats with a history of food restriction.
4/2013Enhanced GABAergic transmission in the central nucleus of the amygdala of genetically selected Marchigian Sardinian rats: alcohol and CRF effects.
10/2003The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roberto Ciccocioppo Research Topics

Disease

38Alcoholism (Alcohol Abuse)
12/2023 - 01/2002
14Substance-Related Disorders (Drug Abuse)
11/2022 - 07/2008
6Cocaine-Related Disorders (Cocaine Addiction)
01/2018 - 05/2004
6Bulimia (Binge Eating)
10/2017 - 05/2009
6Shock
10/2016 - 01/2006
5Opioid-Related Disorders (Opiate Addiction)
07/2023 - 08/2013
4Hypersensitivity (Allergy)
12/2023 - 10/2017
4Obesity
10/2023 - 03/2014
4Substance Withdrawal Syndrome (Withdrawal Symptoms)
12/2019 - 10/2014
3Pain (Aches)
01/2022 - 03/2018
3Type 2 Diabetes Mellitus (MODY)
10/2020 - 04/2011
3Neuralgia (Stump Neuralgia)
01/2019 - 03/2012
3Feeding and Eating Disorders (Eating Disorder)
10/2017 - 12/2010
3Insulin Resistance
12/2016 - 04/2011
3Tobacco Use Disorder (Nicotine Dependence)
11/2016 - 01/2011
3Anorexia
12/2006 - 05/2002
2Inflammation (Inflammations)
10/2023 - 07/2021
2Multiple Sclerosis
01/2021 - 01/2010
2Binge Drinking
10/2020 - 10/2019
2Cognitive Dysfunction
01/2017 - 09/2007
2Hyperphagia (Overeating)
01/2016 - 04/2006
2Partial Epilepsies (Epilepsy, Partial)
07/2013 - 03/2012
2Anxiety Disorders (Anxiety Disorder)
07/2013 - 03/2012
1Malnutrition (Nutritional Deficiencies)
03/2024
1Weight Gain
10/2023
1Weight Loss (Weight Reduction)
10/2023
1Dyslipidemias (Dyslipidemia)
10/2023
1Overweight
10/2023
1Neoplasms (Cancer)
01/2022
1Fatty Liver
07/2021
1Body Weight (Weight, Body)
07/2021

Drug/Important Bio-Agent (IBA)

16NociceptinIBA
01/2023 - 05/2002
13Ethanol (Ethyl Alcohol)IBA
02/2021 - 01/2002
10Opioid Analgesics (Opioids)IBA
07/2023 - 12/2014
6Pioglitazone (Actos)FDA Link
10/2020 - 04/2011
6Nociceptin ReceptorIBA
01/2019 - 05/2002
5EndocannabinoidsIBA
12/2023 - 07/2007
5NeuropeptidesIBA
01/2019 - 11/2009
5CannabinoidsIBA
11/2018 - 07/2007
5Corticotropin-Releasing HormoneIBA
01/2018 - 02/2010
4CRF receptor type 1IBA
01/2018 - 03/2007
4Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA
10/2017 - 10/2003
3anandamide (arachidonylethanolamide)IBA
10/2023 - 07/2008
3Buprenorphine (Subutex)FDA LinkGeneric
07/2023 - 01/2007
3Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
07/2023 - 04/2021
3Opioid Peptides (Opioid Peptide)IBA
01/2023 - 01/2003
3Peptides (Polypeptides)IBA
01/2022 - 02/2010
3Neurotransmitter Agents (Neurotransmitter)IBA
03/2021 - 05/2011
3Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021 - 06/2013
3Pregabalin (Lyrica)FDA Link
01/2019 - 03/2012
3Morphine (MS Contin)FDA LinkGeneric
03/2018 - 08/2013
3Anti-Anxiety Agents (Anxiolytics)IBA
01/2016 - 01/2010
3gamma-Aminobutyric Acid (GABA)IBA
07/2013 - 03/2012
2ElementsIBA
03/2024 - 03/2013
2EnzymesIBA
12/2023 - 01/2011
2Oleic Acid (Oleate)IBA
10/2023 - 11/2018
2LipidsIBA
10/2023 - 01/2021
26'- fluoro- 4',9'- dihydro- N,N- dimethyl- 4- phenylspiro(cyclohexane- 1,1'(3'H)- pyrano(3,4- b)indol)- 4- amineIBA
07/2023 - 01/2017
2Mifepristone (RU 486)FDA Link
01/2023 - 01/2023
2oleoylethanolamideIBA
07/2021 - 01/2016
2palmidrolIBA
01/2021 - 01/2019
2NicotineFDA Link
12/2019 - 01/2011
2LigandsIBA
10/2019 - 11/2018
2CB1 Cannabinoid Receptor (CB1 Receptor)IBA
11/2018 - 07/2008
2R 121919IBA
10/2017 - 08/2014
2PesticidesIBA
01/2017 - 01/2013
2Adrenocorticotropic Hormone (ACTH)FDA Link
11/2016 - 11/2009
2Antidepressive Agents (Antidepressants)IBA
01/2016 - 03/2014
22- (3- (1- (acenaphthen- 1- yl)piperidin- 4- yl)- 2- oxo- 2,3- dihydro- 1H- benzimidazol- 1- yl)- N- methylacetamideIBA
10/2014 - 01/2014
2Aminobutyrates (Aminobutyric Acid)IBA
07/2013 - 03/2012
2cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA
01/2011 - 07/2008
2Dronabinol (THC)FDA LinkGeneric
01/2010 - 09/2007
1Monoacylglycerol LipasesIBA
12/2023
1linoleoyl ethanolamideIBA
10/2023
1CholesterolIBA
10/2023
1Fatty Acids (Saturated Fatty Acids)IBA
10/2023
1Glycerol (Glycerine)FDA LinkGeneric
10/2023
1Triglycerides (Triacylglycerol)IBA
10/2023
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2023
1Interleukin-6 (Interleukin 6)IBA
10/2023
1Arachidonic Acid (Vitamin F)IBA
10/2023
1Palmitic Acid (Hexadecanoic Acid)IBA
10/2023
1Methadone (Dolophine)FDA LinkGeneric
07/2023
1Heroin (Diamorphine)IBA
11/2022
12- (N- cyclopropylmethyl- 4,5- epoxy- 6,14- ethano- 3- hydroxy- 6- methoxymorphinan- 7- yl)- 3,3- dimethylpentan- 2- olIBA
01/2022
1polyoxyethyleneamineIBA
07/2021
1OleylethanolamideIBA
07/2021
1palmitoleic acidIBA
07/2021
1Transcription Factors (Transcription Factor)IBA
01/2021
1Formaldehyde (Formol)FDA Link
01/2021
1N-acylethanolaminesIBA
01/2021
1HydrolasesIBA
01/2021
1CarrageenanIBA
01/2021
1AcidsIBA
01/2021
1amidaseIBA
01/2021

Therapy/Procedure

6Drug Therapy (Chemotherapy)
01/2018 - 10/2003
5Therapeutics
07/2023 - 11/2018
4Injections
10/2017 - 05/2002
1Pain Management
01/2022
1Oral Administration
01/2021